{"id":"florbetaben-f18","rwe":[{"pmid":"29999993","year":"2006","title":"Florbetaben F 18.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"32245565","year":"2021","title":"Preclinical evaluation of [(18)F]D3FSP, deuterated AV-45, for imaging of β-amyloid in the brain.","finding":"","journal":"Nuclear medicine and biology","studyType":"Clinical Study"}],"_fda":{"id":"4bcfe123-9c5b-2f90-e063-6294a90aaa46","set_id":"b0915068-cfd4-4d72-b9f8-7e31fe83cd1e","openfda":{"nui":["N0000177914","N0000175869"],"unii":["TLA7312TOI"],"route":["INTRAVENOUS"],"spl_id":["4bcfe123-9c5b-2f90-e063-6294a90aaa46"],"brand_name":["Neuraceq"],"spl_set_id":["b0915068-cfd4-4d72-b9f8-7e31fe83cd1e"],"package_ndc":["54828-001-30","54828-001-50"],"product_ndc":["54828-001"],"generic_name":["FLORBETABEN F 18"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["FLORBETABEN F-18"],"pharm_class_epc":["Radioactive Diagnostic Agent [EPC]"],"pharm_class_moa":["Positron Emitting Activity [MoA]"],"manufacturer_name":["Lantheus Biosciences Ltd."],"application_number":["NDA204677"],"is_original_packager":[true]},"version":"41","overdosage":["10 OVERDOSAGE In the event of administration of a radiation overdose with NEURACEQ, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition."],"description":["11 DESCRIPTION 11.1 Drug Characteristics NEURACEQ (florbetaben F 18 injection) is a radioactive diagnostic drug for intravenous use. Chemically, florbetaben F 18 is 4-[(E)-2-(4-{2-[2-(2-[ 18 F] fluoroethoxy)ethoxy]ethoxy}phenyl)vinyl]-N-methylaniline. The molecular weight is 358.45 and the structural formula is: NEURACEQ is a sterile, non-pyrogenic, clear solution. Each mL contains up to 3 micrograms of florbetaben and 50 MBq to 5,000 MBq (1.4 mCi to 135 mCi) of florbetaben F 18 at EOS with the following inactive ingredients: 4.4 mg ascorbic acid, 118 mg ethanol, 200 mg macrogol 400, and 28.8 mg sodium ascorbate. The pH of the solution is between 4.5 and 7. structure 11.2 Nuclear Physical Characteristics Fluorine-18 (F 18) decays by positron (ß + ) emission to oxygen-18 and has a physical half-life of 109.8 minutes. The principal photons useful for diagnostic imaging are the coincident pair of 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron (Table 3). Table 3: Principal Radiation Produced from Decay of Fluorine-18 Radiation Energy Level (keV) Abundance (%) Positron 249.8 96.7 Gamma 511 193.4 The point source air-kerma coefficient for F 18 is 3.74E -17 Gy m 2 /(Bq s); this coefficient was formerly defined as the specific gamma-ray constant of 5.7 R/hr/mCi at 1 cm. The first half-value thickness of lead for F 18 gamma rays is approximately 6 mm. The relative reduction of radiation emitted by F 18 that results from various thicknesses of lead shielding is shown in Table 4. The use of ~8 cm of lead will decrease the radiation transmission (i.e., exposure) by a factor of about 10,000. Table 4: Radiation Attenuation of 511 keV by Lead Shielding Shield Thickness cm of Lead Coefficient of Attenuation 0.6 0.5 2 0.1 4 0.01 6 0.001 8 0.0001 For use in correcting for physical decay of this radionuclide, the fractions remaining at selected intervals after calibration are shown in Table 5. Table 5: Physical Decay Chart for Fluorine-18 Minutes Fraction Remaining 0 1.00 15 0.910 30 0.828 60 0.685 110 0.500 220 0.250 440 0.063","11.1 Drug Characteristics NEURACEQ (florbetaben F 18 injection) is a radioactive diagnostic drug for intravenous use. Chemically, florbetaben F 18 is 4-[(E)-2-(4-{2-[2-(2-[ 18 F] fluoroethoxy)ethoxy]ethoxy}phenyl)vinyl]-N-methylaniline. The molecular weight is 358.45 and the structural formula is: NEURACEQ is a sterile, non-pyrogenic, clear solution. Each mL contains up to 3 micrograms of florbetaben and 50 MBq to 5,000 MBq (1.4 mCi to 135 mCi) of florbetaben F 18 at EOS with the following inactive ingredients: 4.4 mg ascorbic acid, 118 mg ethanol, 200 mg macrogol 400, and 28.8 mg sodium ascorbate. The pH of the solution is between 4.5 and 7. structure","11.2 Nuclear Physical Characteristics Fluorine-18 (F 18) decays by positron (ß + ) emission to oxygen-18 and has a physical half-life of 109.8 minutes. The principal photons useful for diagnostic imaging are the coincident pair of 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron (Table 3). Table 3: Principal Radiation Produced from Decay of Fluorine-18 Radiation Energy Level (keV) Abundance (%) Positron 249.8 96.7 Gamma 511 193.4 The point source air-kerma coefficient for F 18 is 3.74E -17 Gy m 2 /(Bq s); this coefficient was formerly defined as the specific gamma-ray constant of 5.7 R/hr/mCi at 1 cm. The first half-value thickness of lead for F 18 gamma rays is approximately 6 mm. The relative reduction of radiation emitted by F 18 that results from various thicknesses of lead shielding is shown in Table 4. The use of ~8 cm of lead will decrease the radiation transmission (i.e., exposure) by a factor of about 10,000. Table 4: Radiation Attenuation of 511 keV by Lead Shielding Shield Thickness cm of Lead Coefficient of Attenuation 0.6 0.5 2 0.1 4 0.01 6 0.001 8 0.0001 For use in correcting for physical decay of this radionuclide, the fractions remaining at selected intervals after calibration are shown in Table 5. Table 5: Physical Decay Chart for Fluorine-18 Minutes Fraction Remaining 0 1.00 15 0.910 30 0.828 60 0.685 110 0.500 220 0.250 440 0.063"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied NEURACEQ (florbetaben F 18 injection) is a clear solution supplied at a concentration of 50 MBq/mL to 5,000 MBq/mL (1.4 mCi/mL to 135 mCi/mL) of florbetaben F 18 in up to 50 mL volume at EOS in a shielded multiple-dose glass vial (NDC 54828-001-50). Storage and Handling Store NEURACEQ in the original container with radiation shielding at room temperature 25°C (77°F); excursions permitted to 2°C to 42°C (36°F to 108°F). NEURACEQ does not contain a preservative. Do not use after the expiration date and time provided on the container label. NEURACEQ multiple-dose vial expires 10 hours after EOS. Dispose of unused product in accordance with all federal, state, and local laws and institutional requirements. This preparation is for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State."],"effective_time":"20260227","clinical_studies":["14 CLINICAL STUDIES 14.1 Evaluation of AD and Other Causes of Cognitive Decline The effectiveness of NEURACEQ was evaluated in two single-arm clinical studies (i.e., Studies 1 and 2) in subjects with a range of cognitive function, including some end-of-life subjects who had agreed to participate in a postmortem brain donation program as well as healthy subjects. Subjects underwent a NEURACEQ injection and scan. Images were interpreted using a clinically applicable binary image interpretation method (negative or positive) by independent readers blinded to all clinical information [see Dosage and Administration ( 2.4 )] . Before image interpretation, all readers underwent either in-person or electronic media training on image interpretation. The truth standard was based on the histopathologic examination using Bielschowsky silver staining (BSS) of six brain regions assessed by a pathology consensus panel blinded to all clinical information (including PET scan results). NEURACEQ results (negative or positive) were pre-specified to correspond with specific histopathology-derived plaque density scores, based upon a modification of the Consortium to Establish a Registry for Alzheimers Disease (CERAD) criteria, which use neuritic plaque counts as a necessary pathological feature of AD (Table 6). For the subject-level truth standard, if any of the six regions were scored as more than sparse, the subject was classified as positive; if none of the regions were assessed as being more than sparse, the subject was classified as negative. Table 6: Categorization of Histopathology and NEURACEQ PET Read Histopathology Categorization NEURACEQ PET Read Neuritic Plaque Counts CERAD Score <1 None Negative 1-5 Sparse 6-19 Moderate Positive > 20 Frequent Study 1 evaluated performance characteristics (sensitivity and specificity) in subjects who died during the study by comparing premortem NEURACEQ PET images to a postmortem truth standard of amyloid beta neuritic plaque density. A total of 205 subjects were dosed with NEURACEQ and imaged. The mean age was 77 years (range 48 to 98 years) and 52% of the subjects were male. By medical history, 137 subjects had AD, 31 had other non-AD dementia, 5 had dementia with Lewy bodies (DLB), and 32 had no clinical evidence of dementia. Among the imaged subjects, 82 subjects died during the study and were included in the primary analysis. The time interval between the NEURACEQ scan and death was less than one year for 45 subjects, between one and two years for 23 subjects, and more than two years for 14 subjects. At autopsy, the subject-level brain amyloid beta neuritic plaque density category was frequent (n = 31), moderate (n = 21), sparse (n = 17), or none (n = 13). Three readers, after undergoing in-person training, interpreted images from the 82 autopsied subjects. Five independent, blinded readers underwent electronic media training and assessed images from the same 82 end-of-life subjects. Study 2 evaluated inter-reader and intra-reader reproducibility of image interpretation using images from subjects with a truth standard (60 subjects who participated in Study 1) and subjects without a truth standard (50 subjects with mild cognitive impairment (MCI), 139 subjects with AD, 30 subjects with other non-AD dementias/disease, 5 subjects with Parkinsons disease (PD), and 170 healthy subjects). Intra-reader reproducibility was assessed with images from 46 subjects (10%). Among the 454 subjects, the mean age was 71 years (range 22 to 98 years), 193 were females, and 353 were White. Readers underwent electronic media training. Among subjects who underwent autopsy (n=82; 52 positive and 30 negative based on histopathology), the sensitivity using the majority interpretation of the in-person trained readers (three readers) was 96.2% (95% CI: 86.8%, 99.5%) and specificity was 80.0% (95% CI: 61.4% to 92.3%). The Sensitivity of the readers trained using electronic media (five readers) was 96.2% (95% CI: 86.8%, 99.5%) and specificity was 76.7% (95% CI: 57.7% to 90.1%). The median (and range) of correct, false negative, and false positive reads were 71 (65 to 73), 2 (0 to 5), 7 (6 to 16), respectively, for electronic media training; and were 75 (74, 75), 1 (1, 2), 6 (5, 7), respectively, for in-person training. Table 7 shows the inter-reader reproducibility for various subject groups in Study 2 a . Inter-reader agreement analyses across all five readers showed an overall Fleiss kappa statistic of 0.79 (95% CI: 0.77, 0.83), which met the pre-specified success criterion (95% CI lower bound > 0.60). The percentage of intra-reader agreement for the five readers ranged from 91% to 98%. Table 7: Inter-Reader Reproducibility of NEURACEQ PET Read Results for Various Subject Groups in Study 2 Subject Group by Cognitive Status and Truth Standard (TS) Positive Scans, n b Kappa (95% CI) Percent of Scans with Inter-Reader Agreement 3 of 5 readers agreed 4 of 5 readers agreed 5 of 5 readers agreed All subjects, n=454 212 0.80 (0.77, 0.83) 6 15 78 Subjects with TS, n=60 37 0.75 (0.67, 0.83) 10 15 75 Subjects without TS, n=394 175 0.80 (0.77, 0.83) 6 15 79 AD, n=176 (37 with TS; 139 no TS) 139 0.77 (0.72, 0.81) 7 10 83 MCI without TS, n=50 28 0.84 (0.75, 0.92) 0 20 80 Other non-AD dementia c , n=40 (5 with TS; 35 no TS) 18 0.65 (0.55, 0.74) 8 33 60 Healthy subjects, n=188 (18 with TS; 170 no TS) 26 0.55 (0.49, 0.58) 7 15 77 a Readers who underwent electronic media training. b Shown is the median number of scans interpreted as positive across the five readers for each group of subjects listed in the first column. c Other non-AD dementia includes dementia with Lewy bodies (DLB), fronto-temporal lobe dementia, vascular dementia, and dementia associated with Parkinson’s disease (PD). 14.2 Selection of Patients Indicated for Amyloid Beta-Directed Therapy Refer to the prescribing information of amyloid beta-directed therapy for description of clinical trials in which the efficacy of amyloid beta PET for selecting patients has been established. Brain amyloid beta PET scans have been used to assess reduction of plaque in some clinical trials of amyloid beta-directed therapies as also described in the prescribing information of the therapeutic products.","14.1 Evaluation of AD and Other Causes of Cognitive Decline The effectiveness of NEURACEQ was evaluated in two single-arm clinical studies (i.e., Studies 1 and 2) in subjects with a range of cognitive function, including some end-of-life subjects who had agreed to participate in a postmortem brain donation program as well as healthy subjects. Subjects underwent a NEURACEQ injection and scan. Images were interpreted using a clinically applicable binary image interpretation method (negative or positive) by independent readers blinded to all clinical information [see Dosage and Administration ( 2.4 )] . Before image interpretation, all readers underwent either in-person or electronic media training on image interpretation. The truth standard was based on the histopathologic examination using Bielschowsky silver staining (BSS) of six brain regions assessed by a pathology consensus panel blinded to all clinical information (including PET scan results). NEURACEQ results (negative or positive) were pre-specified to correspond with specific histopathology-derived plaque density scores, based upon a modification of the Consortium to Establish a Registry for Alzheimers Disease (CERAD) criteria, which use neuritic plaque counts as a necessary pathological feature of AD (Table 6). For the subject-level truth standard, if any of the six regions were scored as more than sparse, the subject was classified as positive; if none of the regions were assessed as being more than sparse, the subject was classified as negative. Table 6: Categorization of Histopathology and NEURACEQ PET Read Histopathology Categorization NEURACEQ PET Read Neuritic Plaque Counts CERAD Score <1 None Negative 1-5 Sparse 6-19 Moderate Positive > 20 Frequent Study 1 evaluated performance characteristics (sensitivity and specificity) in subjects who died during the study by comparing premortem NEURACEQ PET images to a postmortem truth standard of amyloid beta neuritic plaque density. A total of 205 subjects were dosed with NEURACEQ and imaged. The mean age was 77 years (range 48 to 98 years) and 52% of the subjects were male. By medical history, 137 subjects had AD, 31 had other non-AD dementia, 5 had dementia with Lewy bodies (DLB), and 32 had no clinical evidence of dementia. Among the imaged subjects, 82 subjects died during the study and were included in the primary analysis. The time interval between the NEURACEQ scan and death was less than one year for 45 subjects, between one and two years for 23 subjects, and more than two years for 14 subjects. At autopsy, the subject-level brain amyloid beta neuritic plaque density category was frequent (n = 31), moderate (n = 21), sparse (n = 17), or none (n = 13). Three readers, after undergoing in-person training, interpreted images from the 82 autopsied subjects. Five independent, blinded readers underwent electronic media training and assessed images from the same 82 end-of-life subjects. Study 2 evaluated inter-reader and intra-reader reproducibility of image interpretation using images from subjects with a truth standard (60 subjects who participated in Study 1) and subjects without a truth standard (50 subjects with mild cognitive impairment (MCI), 139 subjects with AD, 30 subjects with other non-AD dementias/disease, 5 subjects with Parkinsons disease (PD), and 170 healthy subjects). Intra-reader reproducibility was assessed with images from 46 subjects (10%). Among the 454 subjects, the mean age was 71 years (range 22 to 98 years), 193 were females, and 353 were White. Readers underwent electronic media training. Among subjects who underwent autopsy (n=82; 52 positive and 30 negative based on histopathology), the sensitivity using the majority interpretation of the in-person trained readers (three readers) was 96.2% (95% CI: 86.8%, 99.5%) and specificity was 80.0% (95% CI: 61.4% to 92.3%). The Sensitivity of the readers trained using electronic media (five readers) was 96.2% (95% CI: 86.8%, 99.5%) and specificity was 76.7% (95% CI: 57.7% to 90.1%). The median (and range) of correct, false negative, and false positive reads were 71 (65 to 73), 2 (0 to 5), 7 (6 to 16), respectively, for electronic media training; and were 75 (74, 75), 1 (1, 2), 6 (5, 7), respectively, for in-person training. Table 7 shows the inter-reader reproducibility for various subject groups in Study 2 a . Inter-reader agreement analyses across all five readers showed an overall Fleiss kappa statistic of 0.79 (95% CI: 0.77, 0.83), which met the pre-specified success criterion (95% CI lower bound > 0.60). The percentage of intra-reader agreement for the five readers ranged from 91% to 98%. Table 7: Inter-Reader Reproducibility of NEURACEQ PET Read Results for Various Subject Groups in Study 2 Subject Group by Cognitive Status and Truth Standard (TS) Positive Scans, n b Kappa (95% CI) Percent of Scans with Inter-Reader Agreement 3 of 5 readers agreed 4 of 5 readers agreed 5 of 5 readers agreed All subjects, n=454 212 0.80 (0.77, 0.83) 6 15 78 Subjects with TS, n=60 37 0.75 (0.67, 0.83) 10 15 75 Subjects without TS, n=394 175 0.80 (0.77, 0.83) 6 15 79 AD, n=176 (37 with TS; 139 no TS) 139 0.77 (0.72, 0.81) 7 10 83 MCI without TS, n=50 28 0.84 (0.75, 0.92) 0 20 80 Other non-AD dementia c , n=40 (5 with TS; 35 no TS) 18 0.65 (0.55, 0.74) 8 33 60 Healthy subjects, n=188 (18 with TS; 170 no TS) 26 0.55 (0.49, 0.58) 7 15 77 a Readers who underwent electronic media training. b Shown is the median number of scans interpreted as positive across the five readers for each group of subjects listed in the first column. c Other non-AD dementia includes dementia with Lewy bodies (DLB), fronto-temporal lobe dementia, vascular dementia, and dementia associated with Parkinson’s disease (PD).","14.2 Selection of Patients Indicated for Amyloid Beta-Directed Therapy Refer to the prescribing information of amyloid beta-directed therapy for description of clinical trials in which the efficacy of amyloid beta PET for selecting patients has been established. Brain amyloid beta PET scans have been used to assess reduction of plaque in some clinical trials of amyloid beta-directed therapies as also described in the prescribing information of the therapeutic products."],"adverse_reactions":["6 ADVERSE REACTIONS Most common adverse reactions (incidence ≥ 1%) were injection site pain, injection site erythema, and injection site irritation (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Lantheus Biosciences Ltd. at 1‑833-491-2524 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of NEURACEQ was evaluated in 872 adult subjects who received NEURACEQ by intravenous injection in clinical trials. Of these subjects, 724 received a single dose, 78 received two doses, and 70 received three doses at yearly intervals as part of annual repeat scanning. Table 2 shows adverse reactions reported in 1% of these 1,090 administrations from the clinical trials. Table 2: Adverse Reactions Reported in 1% of NEURACEQ Administrations in Adults in Clinical Trials Adverse Reaction NEURACEQ N=1,090 Administrations % Injection site pain 3.4 Injection site erythema 1.7 Injection site irritation 1.1","6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of NEURACEQ was evaluated in 872 adult subjects who received NEURACEQ by intravenous injection in clinical trials. Of these subjects, 724 received a single dose, 78 received two doses, and 70 received three doses at yearly intervals as part of annual repeat scanning. Table 2 shows adverse reactions reported in 1% of these 1,090 administrations from the clinical trials. Table 2: Adverse Reactions Reported in 1% of NEURACEQ Administrations in Adults in Clinical Trials Adverse Reaction NEURACEQ N=1,090 Administrations % Injection site pain 3.4 Injection site erythema 1.7 Injection site irritation 1.1"],"contraindications":["4 CONTRAINDICATIONS None None."],"description_table":["
Table 3: Principal Radiation Produced from Decay of Fluorine-18
RadiationEnergy Level (keV)Abundance (%)
Positron249.896.7
Gamma511193.4
","
Table 4: Radiation Attenuation of 511 keV by Lead Shielding
Shield Thickness cm of Lead Coefficient of Attenuation
0.60.5
20.1
40.01
60.001
80.0001
","
Table 5: Physical Decay Chart for Fluorine-18
Minutes Fraction Remaining
0 1.00
15 0.910
30 0.828
60 0.685
110 0.500
220 0.250
440 0.063
","
Table 3: Principal Radiation Produced from Decay of Fluorine-18
RadiationEnergy Level (keV)Abundance (%)
Positron249.896.7
Gamma511193.4
","
Table 4: Radiation Attenuation of 511 keV by Lead Shielding
Shield Thickness cm of Lead Coefficient of Attenuation
0.60.5
20.1
40.01
60.001
80.0001
","
Table 5: Physical Decay Chart for Fluorine-18
Minutes Fraction Remaining
0 1.00
15 0.910
30 0.828
60 0.685
110 0.500
220 0.250
440 0.063
"],"recent_major_changes":["Recent Major Changes Indications and Usage (1) 6/2025 Dosage and Administration (2), 6/2025 Image Display and Interpretation (2.4)"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Florbetaben F 18 binds to amyloid beta plaques in the brain and the F 18 isotope produces a positron signal that is detected by a PET scanner. 3 H-florbetaben in vitro binding experiments revealed two binding sites (K d of 16 nM and 135 nM) in frontal cortex homogenates from patients with AD. Binding of florbetaben F 18 to amyloid beta plaques in postmortem brain sections from patients with AD using autoradiography correlated with both immunohistochemical and Bielschowsky silver stains. Florbetaben F 18 did not bind to tau or α-synuclein in tissue from patients with AD. Neither florbetaben F 18 nor non-radioactive florbetaben F 19 bound to AT8 positive tau deposited in brain tissue from patients with frontotemporal dementia (FTD), using autoradiography and immunohistochemistry, respectively. 12.2 Pharmacodynamics Following intravenous administration, florbetaben F 18 crosses the human blood-brain barrier and shows differential retention in brain regions that contain amyloid beta deposits. Differences in signal intensity between brain regions showing specific and non-specific florbetaben F 18 uptake form the basis for the image interpretation method [see Dosage and Administration ( 2.4 )] . 12.3 Pharmacokinetics Following intravenous administration of 300 MBq (8.1 mCi) of NEURACEQ in healthy subjects, approximately 6% of the injected radioactivity was distributed to the brain at 10 minutes post-injection. Florbetaben F 18 plasma concentrations declined by approximately 75% at 20 minutes post-injection, and by approximately 90% at 50 minutes. The F 18 in circulation during the 45-minute to 130-minute imaging window was principally in the form of polar metabolites of florbetaben. Florbetaben F 18 was 98.5% bound to plasma proteins and was eliminated from plasma primarily via the hepatobiliary route with a mean biological half-life of approximately 1 hour. In vitro studies show that metabolism of florbetaben is predominantly catalyzed by CYP2J2 and CYP4F2. At 12 hours post-administration, approximately 30% of the injected radioactivity had been excreted in urine. Almost all F 18 radioactivity in urine was excreted as polar metabolites of florbetaben F 18 and only trace amounts of florbetaben F 18 were detected. In in vitro studies using human liver microsomes, florbetaben did not inhibit cytochrome P450 enzymes at concentrations present in vivo .","12.1 Mechanism of Action Florbetaben F 18 binds to amyloid beta plaques in the brain and the F 18 isotope produces a positron signal that is detected by a PET scanner. 3 H-florbetaben in vitro binding experiments revealed two binding sites (K d of 16 nM and 135 nM) in frontal cortex homogenates from patients with AD. Binding of florbetaben F 18 to amyloid beta plaques in postmortem brain sections from patients with AD using autoradiography correlated with both immunohistochemical and Bielschowsky silver stains. Florbetaben F 18 did not bind to tau or α-synuclein in tissue from patients with AD. Neither florbetaben F 18 nor non-radioactive florbetaben F 19 bound to AT8 positive tau deposited in brain tissue from patients with frontotemporal dementia (FTD), using autoradiography and immunohistochemistry, respectively.","12.2 Pharmacodynamics Following intravenous administration, florbetaben F 18 crosses the human blood-brain barrier and shows differential retention in brain regions that contain amyloid beta deposits. Differences in signal intensity between brain regions showing specific and non-specific florbetaben F 18 uptake form the basis for the image interpretation method [see Dosage and Administration ( 2.4 )] .","12.3 Pharmacokinetics Following intravenous administration of 300 MBq (8.1 mCi) of NEURACEQ in healthy subjects, approximately 6% of the injected radioactivity was distributed to the brain at 10 minutes post-injection. Florbetaben F 18 plasma concentrations declined by approximately 75% at 20 minutes post-injection, and by approximately 90% at 50 minutes. The F 18 in circulation during the 45-minute to 130-minute imaging window was principally in the form of polar metabolites of florbetaben. Florbetaben F 18 was 98.5% bound to plasma proteins and was eliminated from plasma primarily via the hepatobiliary route with a mean biological half-life of approximately 1 hour. In vitro studies show that metabolism of florbetaben is predominantly catalyzed by CYP2J2 and CYP4F2. At 12 hours post-administration, approximately 30% of the injected radioactivity had been excreted in urine. Almost all F 18 radioactivity in urine was excreted as polar metabolites of florbetaben F 18 and only trace amounts of florbetaben F 18 were detected. In in vitro studies using human liver microsomes, florbetaben did not inhibit cytochrome P450 enzymes at concentrations present in vivo ."],"indications_and_usage":["1 INDICATIONS AND USAGE NEURACEQ is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products (1)"],"safe_handling_warning":["2.1 Radiation Safety - Drug Handling Handle NEURACEQ with appropriate safety measures to minimize radiation exposure during administration [ see Warnings and Precautions ( 5.2 )]. Use waterproof gloves and effective radiation shielding, including lead-glass syringe shields when handling and administering NEURACEQ. Radiopharmaceuticals, including NEURACEQ, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. (5.1) Radiation Risk: NEURACEQ contributes to a patient’s long-term cumulative radiation exposure. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration. (2.1, 2.2, 5.2) 5.1 Risk of Image Misinterpretation and Other Errors Errors may occur in the estimation of brain amyloid beta neuritic plaque density during NEURACEQ image interpretation [ see Clinical Studies ( 14 ) ]. The use of clinical information in the interpretation of NEURACEQ images has not been evaluated and may lead to an inaccurate assessment. Severe brain atrophy as well as motion artifacts that result in image distortion may limit the ability to distinguish gray and white matter on a NEURACEQ scan. Perform image interpretation independently of the patient’s clinical information. For cases where there is uncertainty as to the location of cortical signal, use co-registered anatomical imaging to improve localization of signal [see Dosage and Administration ( 2.4 )] . 5.2 Radiation Risk NEURACEQ contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration [ see Dosage and Administration ( 2.1 , 2.2 )] .","5.1 Risk of Image Misinterpretation and Other Errors Errors may occur in the estimation of brain amyloid beta neuritic plaque density during NEURACEQ image interpretation [ see Clinical Studies ( 14 ) ]. The use of clinical information in the interpretation of NEURACEQ images has not been evaluated and may lead to an inaccurate assessment. Severe brain atrophy as well as motion artifacts that result in image distortion may limit the ability to distinguish gray and white matter on a NEURACEQ scan. Perform image interpretation independently of the patient’s clinical information. For cases where there is uncertainty as to the location of cortical signal, use co-registered anatomical imaging to improve localization of signal [see Dosage and Administration ( 2.4 )] .","5.2 Radiation Risk NEURACEQ contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration [ see Dosage and Administration ( 2.1 , 2.2 )] ."],"clinical_studies_table":["
Table 6: Categorization of Histopathology and NEURACEQ PET Read
Histopathology CategorizationNEURACEQ PET Read
Neuritic Plaque CountsCERAD Score
<1NoneNegative
1-5Sparse
6-19ModeratePositive
>20 Frequent
","
Table 7: Inter-Reader Reproducibility of NEURACEQ PET Read Results for Various Subject Groups in Study 2
Subject Group by Cognitive Status and Truth Standard (TS)PositiveScans,n bKappa(95% CI)Percent of Scans with Inter-Reader Agreement
3 of 5 readers agreed4 of 5 readers agreed5 of 5 readers agreed
All subjects, n=4542120.80 (0.77, 0.83)61578
Subjects with TS, n=60370.75 (0.67, 0.83)101575
Subjects without TS, n=3941750.80 (0.77, 0.83)61579
AD, n=176(37 with TS; 139 no TS)1390.77 (0.72, 0.81)71083
MCI without TS, n=50280.84 (0.75, 0.92)02080
Other non-AD dementia c, n=40(5 with TS; 35 no TS)180.65 (0.55, 0.74)83360
Healthy subjects, n=188(18 with TS; 170 no TS)260.55 (0.49, 0.58)71577
","
Table 6: Categorization of Histopathology and NEURACEQ PET Read
Histopathology CategorizationNEURACEQ PET Read
Neuritic Plaque CountsCERAD Score
<1NoneNegative
1-5Sparse
6-19ModeratePositive
>20 Frequent
","
Table 7: Inter-Reader Reproducibility of NEURACEQ PET Read Results for Various Subject Groups in Study 2
Subject Group by Cognitive Status and Truth Standard (TS)PositiveScans,n bKappa(95% CI)Percent of Scans with Inter-Reader Agreement
3 of 5 readers agreed4 of 5 readers agreed5 of 5 readers agreed
All subjects, n=4542120.80 (0.77, 0.83)61578
Subjects with TS, n=60370.75 (0.67, 0.83)101575
Subjects without TS, n=3941750.80 (0.77, 0.83)61579
AD, n=176(37 with TS; 139 no TS)1390.77 (0.72, 0.81)71083
MCI without TS, n=50280.84 (0.75, 0.92)02080
Other non-AD dementia c, n=40(5 with TS; 35 no TS)180.65 (0.55, 0.74)83360
Healthy subjects, n=188(18 with TS; 170 no TS)260.55 (0.49, 0.58)71577
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been performed to evaluate the potential for carcinogenesis, impairment of male or female fertility, or reproductive toxicity by florbetaben F 18. Mutagenesis Florbetaben did not demonstrate mutagenic potential in an in vitro bacterial mutation assay (Ames test) using five strains of Salmonella typhimurium and one strain of Escherichia coli or in an in vitro chromosomal aberration assay using human peripheral lymphocytes in the absence and presence of a metabolic activator.","13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been performed to evaluate the potential for carcinogenesis, impairment of male or female fertility, or reproductive toxicity by florbetaben F 18. Mutagenesis Florbetaben did not demonstrate mutagenic potential in an in vitro bacterial mutation assay (Ames test) using five strains of Salmonella typhimurium and one strain of Escherichia coli or in an in vitro chromosomal aberration assay using human peripheral lymphocytes in the absence and presence of a metabolic activator."],"adverse_reactions_table":["
Table 2: Adverse Reactions Reported in 1% of NEURACEQ Administrations in Adults in Clinical Trials
Adverse Reaction NEURACEQ N=1,090 Administrations %
Injection site pain3.4
Injection site erythema1.7
Injection site irritation1.1
","
Table 2: Adverse Reactions Reported in 1% of NEURACEQ Administrations in Adults in Clinical Trials
Adverse Reaction NEURACEQ N=1,090 Administrations %
Injection site pain3.4
Injection site erythema1.7
Injection site irritation1.1
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Radiation Risk Advise patients of the radiation risk of NEURACEQ. Instruct patients to increase their level of hydration before and after receiving NEURACEQ and to void frequently following administration [see Warnings and Precautions (5.2)] . Pregnancy Inform pregnant women of the potential risks of fetal exposure to radiation doses with NEURACEQ [see Use in Specific Populations (8.1)] . Lactation Advise a lactating woman to temporarily discontinue breastfeeding and to pump and discard breast milk for 24 hours after NEURACEQ administration to minimize radiation exposure to the breastfed infant [see Use in Specific Populations (8.2)] ."],"spl_unclassified_section":["Manufactured for Lantheus Biosciences Ltd. 25 Barnes Wallis Road Fareham, Hampshire, PO15 5TT. United Kingdom. NEURACEQ is a registered trademark of Lantheus Biosciences Ltd."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended amount of radioactivity is 300 MBq (8.1 mCi) administered as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL. (2.2) Follow the injection with an intravenous flush of approximately 10 mL of 0.9% sodium chloride injection. (2.2) Obtain 15-minute to 20-minute PET images starting approximately 45 minutes to 130 minutes after drug administration. (2.3) See full prescribing information for image interpretation and radiation dosimetry. (2.4, 2.5) 2.1 Radiation Safety - Drug Handling Handle NEURACEQ with appropriate safety measures to minimize radiation exposure during administration [ see Warnings and Precautions ( 5.2 )]. Use waterproof gloves and effective radiation shielding, including lead-glass syringe shields when handling and administering NEURACEQ. Radiopharmaceuticals, including NEURACEQ, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides. 2.2 Recommended Dosing and Administration Instructions Recommended Dosage The recommended amount of radioactivity of NEURACEQ is 300 MBq (8.1 mCi) in a total volume of up to 10 mL, administered as a single slow intravenous bolus (6 sec/mL). The maximum mass dose is 30 micrograms. Follow the administration with an intravenous flush of approximately 10 mL of 0.9% sodium chloride injection. Patient Preparation Instruct patients to hydrate before and after NEURACEQ administration and to void before imaging and frequently thereafter following NEURACEQ administration [see Warnings and Precautions ( 5.2 ) ] . Administration Use aseptic technique and radiation shielding to withdraw and administer NEURACEQ. Visually inspect NEURACEQ for particulate matter and discoloration prior to administration. Do not use NEURACEQ if it contains particulate matter or if it is discolored. Do not dilute NEURACEQ. Measure the activity of NEURACEQ with a dose calibrator immediately prior to injection. Verify patency of the indwelling catheter by a test flush with 0.9% sodium chloride injection prior to administration of NEURACEQ. Dispose of unused product in a safe manner in compliance with applicable regulations 2.3 Image Acquisition Guideline Position the patient supine with the head positioned to center the brain, including the cerebellum, in the PET scanner field of view. Tape or other flexible head restraints may be employed to reduce head movement. Acquire 15-minute to 20-minute PET images starting 45 minutes to 130 minutes after NEURACEQ administration. Image reconstruction should include attenuation correction with resulting transaxial pixel sizes between 2 mm and 3 mm. 2.4 Image Display and Interpretation Image Display Display images in the transaxial orientation using gray scale or inverse gray scale. The sagittal and coronal planes may be used for additional orientation purposes. CT or MR images may be helpful for anatomic reference purposes. However, visual assessment should be performed using the axial planes according to the recommended reading methodology. Locate regions which ‘anatomically’ correspond to white matter structures (e.g., the cerebellar white matter or the splenium) for orientation. Review images in a systematic manner, starting with the cerebellum and scrolling up through the lateral temporal and frontal lobes, the posterior cingulate cortex/precuneus, and the parietal lobes. Visual Assessment NEURACEQ images should be interpreted only by readers who successfully complete training provided by the manufacturer. The reader training can be accessed here: https://www.neuraceqreadertraining.com/learn. Perform image interpretation independently of the patient’s clinical features, relying on the recognition of unique image features. Interpret NEURACEQ images based upon the distribution of signal intensity within the cerebral cortex by comparing the signal intensity in the cortical gray matter and the adjacent white matter. Signal intensity in the gray matter is assessed in the following four brain regions: the temporal lobes, the frontal lobes, the posterior cingulate cortex/precuneus, and the parietal lobes. For a gray matter cortical region to be assessed as showing increased signal, the majority of slices from the respective region must be affected. The signal intensity in the cerebellum does not contribute to the scan interpretation. For example, a positive scan may show retained cerebellar gray-white contrast even when the cortical gray-white contrast is lost. Some scans may be difficult to interpret due to image noise, atrophy with a thinned cortex, or image blur. If co-registered computerized tomography (CT) or magnetic resonance (MR) images are available, the CT/MR images may be used to clarify the relationship of the NEURACEQ uptake and the gray matter anatomy [ see Warnings and Precautions ( 5.1 )] . Negative NEURACEQ Scan Signal intensity in gray matter is lower than in white matter in all four brain regions (no amyloid beta deposition). A negative scan indicates sparse to no amyloid beta neuritic plaques. In patients being evaluated for AD and other causes of cognitive decline who have not been treated with amyloid beta-directed therapy, a negative scan is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition and reduces the likelihood that a patient’s cognitive impairment is due to AD. A negative scan result does not preclude the accumulation of amyloid beta in the brain in the future. Positive NEURACEQ Scan Smaller area(s) of signal intensity equal to or higher than that present in white matter extending beyond the white matter rim to the outer cortical margin involving the majority of the slices within at least one of the four brain regions (“moderate” amyloid beta deposition), or a large confluent area of signal intensity equal to or higher than that present in white matter extending beyond the white matter rim to the outer cortical margin and involving the entire region including the majority of slices within at least one of the four brain regions (“pronounced” amyloid beta deposition). There is no known clinical or histopathologic correlation distinguishing “moderate” from “pronounced” amyloid beta deposition. A positive scan establishes the presence of moderate to frequent amyloid beta neuritic plaques. Neuropathological examination has shown that moderate to frequent amyloid beta neuritic plaques are present in patients with AD but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Examples of positive and negative scans for each of the four brain regions are illustrated in Figure 1. Figure 1 Axial view of negative (top row) and positive (bottom row) Neuraceq PET scans Cerebellum: A contrast between the white matter (arrows) and gray matter is seen in both negative and positive scans. Extracerebral signal intensity in the scalp and posterior sagittal sinus (arrowhead) can be seen. Lateral temporal lobes: Spiculated or “mountainous” appearance of the white matter (arrows) is seen in the negative scan, and the signal does not reach the outer rim of the brain (dashed line) due to lower signal intensity in the gray matter. The positive scan shows a “plumped”, smooth appearance of the outer border of the brain parenchyma (dashed line) due to signal intensity in the gray matter. Frontal Lobes: Spiculated appearance of the white matter in the frontal lobes (arrows) is seen in the negative scan. The positive scan shows “plumped”, smooth appearance in these regions due to the increased gray matter signal intensity (dashed line). Posterior cingulate/precuneus: Regions adjacent and posterior to the splenium (arrow) appear as a hypo-intense “hole” (circle) in the negative scan, whereas this hole is “filled-up” (circle) in the positive scan. Parietal lobes: In the negative scan, the midline between the parietal lobes can be easily identified (long arrow); white matter has a spiculated appearance (short arrow) with low signal near the outer rim of the brain (dashed line). In the positive scan, the midline between the parietal lobes is much thinner. The cortical areas are “filled-up” and are smooth in appearance as signal intensity extends to the outer rim of the brain. Quantitative Analysis Quantification of amyloid beta neuritic plaque levels (e.g., Centiloid scale or standardized uptake value ratio (SUVR)) can be used in conjunction with visual assessment and performed with FDA-authorized software indicated for quantification of brain amyloid beta PET scans. Refer to the drug manufacturer’s training materials for qualitative and quantitative assessment and software manufacturers’ documentation for software operation. Figure 2.5 Radiation Dosimetry Estimated radiation absorbed doses for adults from intravenous injection of Neuraceq are shown in Table 1. Table 1 Estimated Radiation Absorbed Doses from Intravenous Injection of Neuraceq Organ/Tissue Mean Absorbed Radiation Dose per Unit Administered Activity [microGy/MBq] Adrenals 13 Brain 13 Breasts 7 Gallbladder Wall 137 Heart Wall 14 Kidneys 24 Liver 39 Lower Large Intestine-Wall 35 Lungs 15 Muscle 10 Osteogenic Cells 15 Ovaries 16 Pancreas 14 Red Marrow 12 Skin 7 Small Intestine 31 Spleen 10 Stomach Wall 12 Testes 9 Thymus 9 Thyroid 8 Upper Large Intestine-Wall 38 Urinary Bladder Wall 70 Uterus 16 Total Body 11 Effective Dose (microSv/MBq) 19 The whole-body effective dose resulting from administration of 300 MBq (8.1 mCi) of NEURACEQ in adults is estimated to be 5.8 mSv. When PET/CT is performed, exposure to radiation will increase by an amount dependent on the settings used in the CT acquisition.","2.2 Recommended Dosing and Administration Instructions Recommended Dosage The recommended amount of radioactivity of NEURACEQ is 300 MBq (8.1 mCi) in a total volume of up to 10 mL, administered as a single slow intravenous bolus (6 sec/mL). The maximum mass dose is 30 micrograms. Follow the administration with an intravenous flush of approximately 10 mL of 0.9% sodium chloride injection. Patient Preparation Instruct patients to hydrate before and after NEURACEQ administration and to void before imaging and frequently thereafter following NEURACEQ administration [see Warnings and Precautions ( 5.2 ) ] . Administration Use aseptic technique and radiation shielding to withdraw and administer NEURACEQ. Visually inspect NEURACEQ for particulate matter and discoloration prior to administration. Do not use NEURACEQ if it contains particulate matter or if it is discolored. Do not dilute NEURACEQ. Measure the activity of NEURACEQ with a dose calibrator immediately prior to injection. Verify patency of the indwelling catheter by a test flush with 0.9% sodium chloride injection prior to administration of NEURACEQ. Dispose of unused product in a safe manner in compliance with applicable regulations","2.3 Image Acquisition Guideline Position the patient supine with the head positioned to center the brain, including the cerebellum, in the PET scanner field of view. Tape or other flexible head restraints may be employed to reduce head movement. Acquire 15-minute to 20-minute PET images starting 45 minutes to 130 minutes after NEURACEQ administration. Image reconstruction should include attenuation correction with resulting transaxial pixel sizes between 2 mm and 3 mm.","2.4 Image Display and Interpretation Image Display Display images in the transaxial orientation using gray scale or inverse gray scale. The sagittal and coronal planes may be used for additional orientation purposes. CT or MR images may be helpful for anatomic reference purposes. However, visual assessment should be performed using the axial planes according to the recommended reading methodology. Locate regions which ‘anatomically’ correspond to white matter structures (e.g., the cerebellar white matter or the splenium) for orientation. Review images in a systematic manner, starting with the cerebellum and scrolling up through the lateral temporal and frontal lobes, the posterior cingulate cortex/precuneus, and the parietal lobes. Visual Assessment NEURACEQ images should be interpreted only by readers who successfully complete training provided by the manufacturer. The reader training can be accessed here: https://www.neuraceqreadertraining.com/learn. Perform image interpretation independently of the patient’s clinical features, relying on the recognition of unique image features. Interpret NEURACEQ images based upon the distribution of signal intensity within the cerebral cortex by comparing the signal intensity in the cortical gray matter and the adjacent white matter. Signal intensity in the gray matter is assessed in the following four brain regions: the temporal lobes, the frontal lobes, the posterior cingulate cortex/precuneus, and the parietal lobes. For a gray matter cortical region to be assessed as showing increased signal, the majority of slices from the respective region must be affected. The signal intensity in the cerebellum does not contribute to the scan interpretation. For example, a positive scan may show retained cerebellar gray-white contrast even when the cortical gray-white contrast is lost. Some scans may be difficult to interpret due to image noise, atrophy with a thinned cortex, or image blur. If co-registered computerized tomography (CT) or magnetic resonance (MR) images are available, the CT/MR images may be used to clarify the relationship of the NEURACEQ uptake and the gray matter anatomy [ see Warnings and Precautions ( 5.1 )] . Negative NEURACEQ Scan Signal intensity in gray matter is lower than in white matter in all four brain regions (no amyloid beta deposition). A negative scan indicates sparse to no amyloid beta neuritic plaques. In patients being evaluated for AD and other causes of cognitive decline who have not been treated with amyloid beta-directed therapy, a negative scan is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition and reduces the likelihood that a patient’s cognitive impairment is due to AD. A negative scan result does not preclude the accumulation of amyloid beta in the brain in the future. Positive NEURACEQ Scan Smaller area(s) of signal intensity equal to or higher than that present in white matter extending beyond the white matter rim to the outer cortical margin involving the majority of the slices within at least one of the four brain regions (“moderate” amyloid beta deposition), or a large confluent area of signal intensity equal to or higher than that present in white matter extending beyond the white matter rim to the outer cortical margin and involving the entire region including the majority of slices within at least one of the four brain regions (“pronounced” amyloid beta deposition). There is no known clinical or histopathologic correlation distinguishing “moderate” from “pronounced” amyloid beta deposition. A positive scan establishes the presence of moderate to frequent amyloid beta neuritic plaques. Neuropathological examination has shown that moderate to frequent amyloid beta neuritic plaques are present in patients with AD but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Examples of positive and negative scans for each of the four brain regions are illustrated in Figure 1. Figure 1 Axial view of negative (top row) and positive (bottom row) Neuraceq PET scans Cerebellum: A contrast between the white matter (arrows) and gray matter is seen in both negative and positive scans. Extracerebral signal intensity in the scalp and posterior sagittal sinus (arrowhead) can be seen. Lateral temporal lobes: Spiculated or “mountainous” appearance of the white matter (arrows) is seen in the negative scan, and the signal does not reach the outer rim of the brain (dashed line) due to lower signal intensity in the gray matter. The positive scan shows a “plumped”, smooth appearance of the outer border of the brain parenchyma (dashed line) due to signal intensity in the gray matter. Frontal Lobes: Spiculated appearance of the white matter in the frontal lobes (arrows) is seen in the negative scan. The positive scan shows “plumped”, smooth appearance in these regions due to the increased gray matter signal intensity (dashed line). Posterior cingulate/precuneus: Regions adjacent and posterior to the splenium (arrow) appear as a hypo-intense “hole” (circle) in the negative scan, whereas this hole is “filled-up” (circle) in the positive scan. Parietal lobes: In the negative scan, the midline between the parietal lobes can be easily identified (long arrow); white matter has a spiculated appearance (short arrow) with low signal near the outer rim of the brain (dashed line). In the positive scan, the midline between the parietal lobes is much thinner. The cortical areas are “filled-up” and are smooth in appearance as signal intensity extends to the outer rim of the brain. Quantitative Analysis Quantification of amyloid beta neuritic plaque levels (e.g., Centiloid scale or standardized uptake value ratio (SUVR)) can be used in conjunction with visual assessment and performed with FDA-authorized software indicated for quantification of brain amyloid beta PET scans. Refer to the drug manufacturer’s training materials for qualitative and quantitative assessment and software manufacturers’ documentation for software operation. Figure","2.5 Radiation Dosimetry Estimated radiation absorbed doses for adults from intravenous injection of Neuraceq are shown in Table 1. Table 1 Estimated Radiation Absorbed Doses from Intravenous Injection of Neuraceq Organ/Tissue Mean Absorbed Radiation Dose per Unit Administered Activity [microGy/MBq] Adrenals 13 Brain 13 Breasts 7 Gallbladder Wall 137 Heart Wall 14 Kidneys 24 Liver 39 Lower Large Intestine-Wall 35 Lungs 15 Muscle 10 Osteogenic Cells 15 Ovaries 16 Pancreas 14 Red Marrow 12 Skin 7 Small Intestine 31 Spleen 10 Stomach Wall 12 Testes 9 Thymus 9 Thyroid 8 Upper Large Intestine-Wall 38 Urinary Bladder Wall 70 Uterus 16 Total Body 11 Effective Dose (microSv/MBq) 19 The whole-body effective dose resulting from administration of 300 MBq (8.1 mCi) of NEURACEQ in adults is estimated to be 5.8 mSv. When PET/CT is performed, exposure to radiation will increase by an amount dependent on the settings used in the CT acquisition."],"spl_product_data_elements":["Neuraceq Florbetaben F 18 ALCOHOL POLYETHYLENE GLYCOL 400 ASCORBIC ACID SODIUM ASCORBATE WATER FLORBETABEN F-18 FLORBETABEN F-18"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 50 MBq/mL to 5,000 MBq/mL (1.4 mCi/mL to 135 mCi/mL) of florbetaben F 18 in up to 50 mL volume at end of synthesis (EOS) as a clear solution in a multiple-dose vial. Injection: 50 MBq/mL to 5,000 MBq/mL (1.4 mCi/mL to 135 mCi/mL) of florbetaben F 18 in up to 50 mL volume at end of synthesis in a multiple-dose vial"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available data on NEURACEQ use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with florbetaben F 18 to evaluate its effect on female reproduction and embryo-fetal development. All radiopharmaceuticals, including NEURACEQ, have the potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiation dose. If considering NEURACEQ administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 8.2 Lactation Risk Summary There are no data on the presence of florbetaben F 18 in human milk, the effects on the breastfed infant, or the effects on milk production. Exposure of NEURACEQ to a breastfed infant can be minimized by temporary discontinuation of breastfeeding (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NEURACEQ and any potential adverse effects on the breastfed child from NEURACEQ or from the underlying maternal condition. Clinical Considerations To decrease radiation exposure to the breastfed infant, advise a lactating woman to pump and discard breast milk for 24 hours after administration of NEURACEQ Lactation: Temporarily discontinue breastfeeding. A lactating woman should pump and discard breast milk for 24 hours after NEURACEQ administration (8.2). 8.4 Pediatric Use The safety and effectiveness of NEURACEQ have not been established in pediatric patients. 8.5 Geriatric Use Of the 872 subjects in clinical studies of NEURACEQ, 603 (69%) subjects were 65 years of age and older, while 304 (35%) subjects were 75 years of age and older. No overall differences in safety or effectiveness were observed between subjects 65 years of age and older and younger adult subjects.","8.1 Pregnancy Risk Summary There are no available data on NEURACEQ use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with florbetaben F 18 to evaluate its effect on female reproduction and embryo-fetal development. All radiopharmaceuticals, including NEURACEQ, have the potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiation dose. If considering NEURACEQ administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","8.2 Lactation Risk Summary There are no data on the presence of florbetaben F 18 in human milk, the effects on the breastfed infant, or the effects on milk production. Exposure of NEURACEQ to a breastfed infant can be minimized by temporary discontinuation of breastfeeding (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NEURACEQ and any potential adverse effects on the breastfed child from NEURACEQ or from the underlying maternal condition. Clinical Considerations To decrease radiation exposure to the breastfed infant, advise a lactating woman to pump and discard breast milk for 24 hours after administration of NEURACEQ Lactation: Temporarily discontinue breastfeeding. A lactating woman should pump and discard breast milk for 24 hours after NEURACEQ administration (8.2).","8.4 Pediatric Use The safety and effectiveness of NEURACEQ have not been established in pediatric patients.","8.5 Geriatric Use Of the 872 subjects in clinical studies of NEURACEQ, 603 (69%) subjects were 65 years of age and older, while 304 (35%) subjects were 75 years of age and older. No overall differences in safety or effectiveness were observed between subjects 65 years of age and older and younger adult subjects."],"dosage_and_administration_table":["
Table 1 Estimated Radiation Absorbed Doses from Intravenous Injection of Neuraceq
Organ/TissueMean Absorbed Radiation Dose per Unit Administered Activity [microGy/MBq]
Adrenals13
Brain13
Breasts7
Gallbladder Wall137
Heart Wall14
Kidneys24
Liver39
Lower Large Intestine-Wall35
Lungs15
Muscle10
Osteogenic Cells15
Ovaries16
Pancreas14
Red Marrow12
Skin7
Small Intestine31
Spleen10
Stomach Wall12
Testes9
Thymus9
Thyroid8
Upper Large Intestine-Wall38
Urinary Bladder Wall70
Uterus16
Total Body11
Effective Dose (microSv/MBq)19
","
Table 1 Estimated Radiation Absorbed Doses from Intravenous Injection of Neuraceq
Organ/TissueMean Absorbed Radiation Dose per Unit Administered Activity [microGy/MBq]
Adrenals13
Brain13
Breasts7
Gallbladder Wall137
Heart Wall14
Kidneys24
Liver39
Lower Large Intestine-Wall35
Lungs15
Muscle10
Osteogenic Cells15
Ovaries16
Pancreas14
Red Marrow12
Skin7
Small Intestine31
Spleen10
Stomach Wall12
Testes9
Thymus9
Thyroid8
Upper Large Intestine-Wall38
Urinary Bladder Wall70
Uterus16
Total Body11
Effective Dose (microSv/MBq)19
"],"package_label_principal_display_panel":["Neuraceq 50 mL Vial Label Vial label_2025.jpg","Neuraceq Shield Label for 50 mL Vial Shield label_2025.jpg"]},"tags":[{"label":"Radioactive Diagnostic Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Amyloid beta A4 protein","category":"target"},{"label":"APP","category":"gene"},{"label":"V09AX06","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Positron emission tomography","category":"indication"},{"label":"Piramal Imaging","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Injection site pain","drugRate":"3.4%","severity":"mild","_validated":true},{"effect":"Injection site irritation","drugRate":"1.1%","severity":"mild","_validated":true},{"effect":"Injection site erythema","drugRate":"1.7%","severity":"mild","_validated":true}],"specialPopulations":{"Lactation":"There are no data on the presence of florbetaben 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben 18 injection on milk production. Exposure of Neuraceq to breastfed infant can be minimized by temporary discontinuation of breastfeeding [see Clinical Considerations]. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical judgement.","Pregnancy":"There are no available data on Neuraceq use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Neuraceq. All radiopharmaceuticals, including Neuraceq, have potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively."}},"trials":[],"aliases":[],"company":"Piramal Imaging","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2029-03-18","territory":"US","patentNumber":"7807135"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLORBETABEN F18","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:39:42.174202+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:39:42.174092+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:39:47.512313+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLORBETABEN F18","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:39:47.720172+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:40.849907+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:40.849944+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:40.849948+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL566752/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:39:48.421943+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA204677","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:40.849952+00:00"}},"allNames":"neuraceq","offLabel":[],"synonyms":["florbetaben F18","neuraceq","florbetaben (18F)","florbetaben F-18"],"timeline":[{"date":"2014-03-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Piramal Imaging)"}],"aiSummary":"Neuraceq (Florbetaben F18) is a radioactive diagnostic agent developed by Piramal Imaging for positron emission tomography (PET) imaging. It targets the amyloid beta A4 protein, which is associated with Alzheimer's disease. Neuraceq is used to visualize amyloid plaques in the brain, helping diagnose Alzheimer's disease. The commercial status of Neuraceq is patented, and it was FDA-approved in 2014. Key safety considerations include radiation exposure and potential allergic reactions.","approvals":[{"date":"2014-03-19","orphan":false,"company":"PIRAMAL IMAGING","regulator":"FDA"}],"brandName":"Neuraceq","ecosystem":[{"indication":"Positron emission tomography","otherDrugs":[{"name":"AMMONIA N-13","slug":"ammonia-n-13","company":"Feinstein"},{"name":"Florbetapir F-18","slug":"florbetapir-f-18","company":"Avid Radiopharms Inc"},{"name":"Flutemetamol (18F)","slug":"flutemetamol-(18f)","company":"Ge Healthcare"},{"name":"Gallium Ga 68 dotatate","slug":"gallium-ga-68-dotatate","company":"Advanced Accelerator Applications Usa Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Amyloid beta A4 protein","novelty":"Follow-on","targets":[{"gene":"APP","source":"DrugCentral","target":"Amyloid beta A4 protein","protein":"Amyloid beta A4 protein"}],"moaClass":"Positron Emitting Activity","modality":"Small Molecule","drugClass":"Radioactive Diagnostic Agent [EPC]","explanation":"","oneSentence":"","technicalDetail":"Neuraceq is a small molecule radioactive diagnostic agent that binds to amyloid beta A4 protein with high affinity, allowing for specific visualization of amyloid plaques in the brain through positron emission tomography (PET) imaging."},"commercial":{"launchDate":"2014","_launchSource":"DrugCentral (FDA 2014-03-19, PIRAMAL IMAGING)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4818","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLORBETABEN%20F18","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLORBETABEN F18","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:31:41.183031","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:39:51.233553+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"Flutemetamol (18F)","drugSlug":"flutemetamol-(18f)","fdaApproval":"2013-10-25","relationship":"same-class"},{"drugName":"Florbetapir F-18","drugSlug":"florbetapir-f-18","fdaApproval":"2012-04-06","patentExpiry":"Apr 30, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"flortaucipir F 18","drugSlug":"flortaucipir-f-18","fdaApproval":"2020-05-28","relationship":"same-class"}],"genericName":"florbetaben f18","indications":{"approved":[{"name":"Positron emission tomography","source":"DrugCentral","snomedId":82918005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"flutemetamol-(18f)","brandName":"Flutemetamol (18F)","genericName":"Flutemetamol (18F)","approvalYear":"2013","relationship":"same-class"},{"drugId":"florbetapir-f-18","brandName":"Florbetapir F-18","genericName":"Florbetapir F-18","approvalYear":"2012","relationship":"same-class"},{"drugId":"flortaucipir-f-18","brandName":"flortaucipir F 18","genericName":"flortaucipir F 18","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02669225","phase":"EARLY_PHASE1","title":"Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2016-05-02","conditions":["Normal Physiology"],"enrollment":22,"completionDate":"2018-07-11"},{"nctId":"NCT07169630","phase":"PHASE1","title":"PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2026-04-01","conditions":["Alzheimer s Disease","Mild Cognitive Impairment","Healthy"],"enrollment":90,"completionDate":"2030-04-11"},{"nctId":"NCT05617014","phase":"","title":"Alzheimer's Disease Neuroimaging Initiative 4","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern California","startDate":"2023-06-09","conditions":["Mild Cognitive Impairment","Alzheimer Disease","Dementia"],"enrollment":1500,"completionDate":"2027-07-31"},{"nctId":"NCT03507257","phase":"","title":"Longitudinal Early-onset Alzheimer's Disease Study Protocol","status":"RECRUITING","sponsor":"Indiana University","startDate":"2018-04-30","conditions":["Early Onset Alzheimer Disease","Alzheimer Disease","Mild Cognitive Impairment"],"enrollment":850,"completionDate":"2026-05-31"},{"nctId":"NCT04396873","phase":"PHASE1","title":"PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2021-08-17","conditions":["Parkinson's Disease","Dementia","Alzheimer's Disease","ALS","Mild Cognitive Impairment"],"enrollment":184,"completionDate":"2030-10-03"},{"nctId":"NCT06932809","phase":"EARLY_PHASE1","title":"Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-05-09","conditions":["Tauopathies"],"enrollment":90,"completionDate":"2030-04"},{"nctId":"NCT06790394","phase":"PHASE1","title":"Test-retest Study With [18F]FBB in Cardiac Amyloidosis","status":"RECRUITING","sponsor":"Life Molecular Imaging GmbH","startDate":"2025-10-21","conditions":["Cardiac Amyloidosis"],"enrollment":15,"completionDate":"2026-09"},{"nctId":"NCT05184088","phase":"PHASE3","title":"Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis","status":"RECRUITING","sponsor":"Life Molecular Imaging GmbH","startDate":"2023-01-13","conditions":["Cardiac Amyloidosis","AL Amyloidosis","ATTR Amyloidosis"],"enrollment":200,"completionDate":"2026-03"},{"nctId":"NCT06032026","phase":"EARLY_PHASE1","title":"Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-20","conditions":["Tauopathies"],"enrollment":70,"completionDate":"2028-07-31"},{"nctId":"NCT05361382","phase":"PHASE1","title":"Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tharick Pascoal","startDate":"2022-03-02","conditions":["Alzheimer Disease"],"enrollment":822,"completionDate":"2027-05-31"},{"nctId":"NCT03706261","phase":"PHASE1","title":"Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults","status":"COMPLETED","sponsor":"Adam Brickman","startDate":"2019-03-22","conditions":["Alzheimer Disease"],"enrollment":145,"completionDate":"2023-07-14"},{"nctId":"NCT04576793","phase":"PHASE2","title":"Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease","status":"RECRUITING","sponsor":"Patrick Lao","startDate":"2020-11-17","conditions":["Alzheimer Disease"],"enrollment":100,"completionDate":"2026-05-31"},{"nctId":"NCT05783934","phase":"NA","title":"Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT","status":"COMPLETED","sponsor":"Istituti Clinici Scientifici Maugeri SpA","startDate":"2021-07-27","conditions":["Multiple Sclerosis"],"enrollment":6,"completionDate":"2024-01-09"},{"nctId":"NCT04392960","phase":"NA","title":"Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2020-07-22","conditions":["AL Amyloidosis"],"enrollment":69,"completionDate":"2025-06-30"},{"nctId":"NCT04840979","phase":"PHASE2","title":"Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease","status":"RECRUITING","sponsor":"Columbia University","startDate":"2021-05-11","conditions":["Alzheimer Disease"],"enrollment":250,"completionDate":"2026-12"},{"nctId":"NCT06303921","phase":"EARLY_PHASE1","title":"Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-02-16","conditions":["Tauopathies"],"enrollment":70,"completionDate":"2029-02"},{"nctId":"NCT03744312","phase":"PHASE1,PHASE2","title":"Imaging Inflammation in Alzheimer's Disease With 11C-ER176","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-09-10","conditions":["Alzheimer Disease"],"enrollment":9,"completionDate":"2022-07-20"},{"nctId":"NCT03057938","phase":"PHASE2","title":"Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study","status":"WITHDRAWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2020-07","conditions":["Subjective Cognitive Decline"],"enrollment":0,"completionDate":"2022-06"},{"nctId":"NCT02831283","phase":"PHASE2","title":"Imaging Inflammation in Alzheimer's Disease","status":"COMPLETED","sponsor":"Patrick Lao","startDate":"2016-06","conditions":["Alzheimer's Disease"],"enrollment":60,"completionDate":"2022-12"},{"nctId":"NCT03616496","phase":"NA","title":"Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2019-06-06","conditions":["Cardiac Amyloidosis"],"enrollment":67,"completionDate":"2025-02-10"},{"nctId":"NCT04105634","phase":"EARLY_PHASE1","title":"Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2019-10-01","conditions":["Cardiac Amyloidosis"],"enrollment":3,"completionDate":"2024-10-14"},{"nctId":"NCT04720001","phase":"","title":"Florbetaben PET Imaging in PPA","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2018-08-23","conditions":["Primary Progressive Aphasia","Alzheimer Disease"],"enrollment":1,"completionDate":"2021-02-26"},{"nctId":"NCT04510168","phase":"","title":"Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease","status":"COMPLETED","sponsor":"Jose Gutierrez, MD, MPH","startDate":"2020-09-18","conditions":["Alzheimer Disease","Dementia"],"enrollment":238,"completionDate":"2024-04-17"},{"nctId":"NCT05337774","phase":"PHASE1","title":"Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury","status":"TERMINATED","sponsor":"Life Molecular Imaging SA","startDate":"2021-06-07","conditions":["Mild Traumatic Brain Injury"],"enrollment":18,"completionDate":"2022-04-30"},{"nctId":"NCT06330077","phase":"PHASE2","title":"Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03","conditions":["Multiple Sclerosis","Remitting Relapsing Multiple Sclerosis"],"enrollment":60,"completionDate":"2027-06"},{"nctId":"NCT05270083","phase":"NA","title":"Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2017-07-13","conditions":["Concussion, Brain"],"enrollment":15,"completionDate":"2019-10-10"},{"nctId":"NCT06048601","phase":"NA","title":"18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis","status":"UNKNOWN","sponsor":"Fondazione Toscana Gabriele Monasterio","startDate":"2023-01-26","conditions":["Amyloid","Amyloid Cardiomyopathy"],"enrollment":150,"completionDate":"2025-01-31"},{"nctId":"NCT05147532","phase":"NA","title":"Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-01-24","conditions":["Multiple Sclerosis","Inflammatory Disease"],"enrollment":80,"completionDate":"2024-05"},{"nctId":"NCT05527288","phase":"NA","title":"A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population","status":"COMPLETED","sponsor":"Sinotau Pharmaceutical Group","startDate":"2021-01-28","conditions":["Alzheimer Disease","Dementia","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Tauopathies","Neurodegenerative Diseases","Neurocognitive Disorders","Mental Disorders"],"enrollment":50,"completionDate":"2021-09-12"},{"nctId":"NCT02362880","phase":"NA","title":"Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study","status":"TERMINATED","sponsor":"Judit Pich Martínez","startDate":"2015-02","conditions":["Alzheimer Disease"],"enrollment":32,"completionDate":"2019-01"},{"nctId":"NCT02664571","phase":"NA","title":"Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2020-07","conditions":["Amyloid Cerebral Angiopathy","Alzheimer Disease"],"enrollment":0,"completionDate":"2021-07"},{"nctId":"NCT04055532","phase":"","title":"Biomarkers in Neurodegenerative Diseases","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2019-10-01","conditions":["Mild Cognitive Impairment (MCI)","Alzheimer Disease (AD)","Dementia With Lewy Bodies (DLB)","Frontotemporal Lobar Degeneration (FTLD)","Parkinsons Disease With Dementia (PDD)","Transient Epileptic Amnesia (TEA)","Temporal Lobe Epilepsy (TLE)","Spinocerebellar Ataxias (SCA)","HIV Associated Neurocognitive Disorder (HAND)","Amyotrophic Lateral Sclerosis (ALS)","Primary Lateral Sclerosis (PLS)"],"enrollment":0,"completionDate":"2025-10-01"},{"nctId":"NCT03075007","phase":"","title":"Brain Vascular Disease in Aging and Dementia","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-05-23","conditions":["Alzheimer Disease","White Matter Hyperintensities","Dementia","Aging"],"enrollment":48,"completionDate":"2019-08-31"},{"nctId":"NCT03119558","phase":"EARLY_PHASE1","title":"PET/MRI Evaluation of Cardiac Amyloid","status":"COMPLETED","sponsor":"Stanford University","startDate":"2016-05-26","conditions":["Cardiac Amyloidosis"],"enrollment":9,"completionDate":"2018-08-28"},{"nctId":"NCT02556502","phase":"NA","title":"18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2015-11","conditions":["Amyloid PET Imaging"],"enrollment":40,"completionDate":"2017-11"},{"nctId":"NCT03779815","phase":"NA","title":"Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography","status":"COMPLETED","sponsor":"Ulsan University Hospital","startDate":"2018-08-20","conditions":["Multiple Myeloma"],"enrollment":14,"completionDate":"2019-02-28"},{"nctId":"NCT02681172","phase":"PHASE4","title":"Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD","status":"COMPLETED","sponsor":"Piramal Imaging Limited","startDate":"2015-10","conditions":["Alzheimer's Disease (AD)"],"enrollment":218,"completionDate":"2016-11"},{"nctId":"NCT01297114","phase":"","title":"Imaging of Cognition, Learning, and Memory in Aging","status":"COMPLETED","sponsor":"Yaakov Stern","startDate":"2011-03","conditions":["Alzheimer's Disease"],"enrollment":294,"completionDate":"2017-10-01"},{"nctId":"NCT02531360","phase":"EARLY_PHASE1","title":"Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies","status":"COMPLETED","sponsor":"Molecular NeuroImaging","startDate":"2015-05","conditions":["Alzheimer's Disease (AD)","Progressive Supranuclear Palsy (PSP)","Cortical Basal Syndrome (CBS)","Frontal Temporal Dementia (FTD)"],"enrollment":7,"completionDate":"2016-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Neuraceq"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"219505","NDDF":"015462","UNII":"TLA7312TOI","CHEBI":"CHEBI:79033","INN_ID":"9184","RXNORM":"1492940","UMLSCUI":"C3818757","chemblId":"CHEMBL566752","ChEMBL_ID":"CHEMBL566752","DRUGBANK_ID":"DB09148","PUBCHEM_CID":"11501341","SNOMEDCT_US":"712736002"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","company":"Life Molecular Imaging, SA","brandName":"Neuraceq","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2014-","companyName":"Piramal Imaging","relationship":"Original Developer"}],"publicationCount":2,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"V09AX06","allCodes":["V09AX06"]},"biosimilarFilings":[],"originalDeveloper":"Piramal Imaging","recentPublications":[{"date":"2006","pmid":"29999993","title":"Florbetaben F 18.","journal":""},{"date":"2021 Jan","pmid":"32245565","title":"Preclinical evaluation of [(18)F]D3FSP, deuterated AV-45, for imaging of β-amyloid in the brain.","journal":"Nuclear medicine and biology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Piramal Imaging","companyId":"piramal-imaging","modality":"Small molecule","firstApprovalDate":"2014","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-03-19T00:00:00.000Z","mah":"PIRAMAL IMAGING","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"7807135","territory":"US","patent_type":null,"expiry_date":"2029-03-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:39:51.233553+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}